Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.
ASCO 2020: Update on Genitourinary Cancers
Neeraj Agarwal, MD, discusses the rationale for novel combination therapies in metastatic castration-resistant prostate cancer.
Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.
Neeraj Agarwal, MD, discusses the COSMIC-021 trial, the findings from cohort 6 in metastatic castration-resistant prostate cancer, and the planned phase 3 trial that will evaluate the combination on a larger scale.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5